Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer
- PMID: 15623462
- DOI: 10.1207/s15327914nc5002_5
Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer
Abstract
Dietary indoles, present in Brassica plants such as cabbage, broccoli, and Brussels sprouts, have been shown to provide potential protection against hormone-dependent cancers. 3,3'-Diindolylmethane (DIM) is under study as one of the main protective indole metabolites. Postmenopausal women aged 50-70 yr from Marin County, California, with a history of early-stage breast cancer, were screened for interest and eligibility in this pilot study on the effect of absorbable DIM (BioResponse-DIM) supplements on urinary hormone metabolites. The treatment group received daily DIM (108 mg DIM/day) supplements for 30 days, and the control group received a placebo capsule daily for 30 days. Urinary metabolite analysis included 2-hydroxyestrone (2-OHE1), 16-alpha hydroxyestrone (16alpha-OHE1), DIM, estrone (El), estradiol(E2), estriol (E3), 6beta-hydroxycortisol (6beta-OHC), and cortisol in the first morning urine sample before intervention and 31 days after intervention. Nineteen women completed the study,for a total of 10 in the treatment group and 9 in the placebo group. DIM-treated subjects, relative to placebo, showed a significant increase in levels of2-OHE1 (P=0. 020), DIM (P =0. 045), and cortisol (P = 0.039), and a nonsignificant increase of 47% in the 2-OHE1/16alpha-OHE1 ratio from 1.46 to 2.14 (P=0.059). In this pilot study, DIM increased the 2-hydroxylation of estrogen urinary metabolites.
Similar articles
-
A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer.Environ Health Perspect. 1997 Apr;105 Suppl 3(Suppl 3):601-5. doi: 10.1289/ehp.97105s3601. Environ Health Perspect. 1997. PMID: 9168002 Free PMC article.
-
A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.Breast Cancer Res Treat. 2017 Aug;165(1):97-107. doi: 10.1007/s10549-017-4292-7. Epub 2017 May 30. Breast Cancer Res Treat. 2017. PMID: 28560655 Free PMC article. Clinical Trial.
-
Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women.J Natl Cancer Inst. 1999 Jun 16;91(12):1067-72. doi: 10.1093/jnci/91.12.1067. J Natl Cancer Inst. 1999. PMID: 10379970
-
Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites.Altern Med Rev. 2002 Apr;7(2):112-29. Altern Med Rev. 2002. PMID: 11991791 Review.
-
[Estrogen-dependent neoplasia - what is the significance of estradiol metabolites].Zentralbl Gynakol. 2003 Nov;125(11):458-66. doi: 10.1055/s-2003-44575. Zentralbl Gynakol. 2003. PMID: 14634875 Review. German.
Cited by
-
Chemopreventive Agent 3,3'-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells.Int J Mol Sci. 2020 Jun 30;21(13):4642. doi: 10.3390/ijms21134642. Int J Mol Sci. 2020. PMID: 32629830 Free PMC article.
-
The effect of oral 3,3'-diindolylmethane supplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers.Fam Cancer. 2015 Jun;14(2):281-6. doi: 10.1007/s10689-015-9783-2. Fam Cancer. 2015. PMID: 25613194
-
3,3'-Diindolylmethane plus Eflornithine suppress DNA Replication and Cell Cycle in Esophageal Squamous Cell Carcinoma in vivo.J Cancer. 2022 May 16;13(8):2607-2619. doi: 10.7150/jca.65506. eCollection 2022. J Cancer. 2022. PMID: 35711839 Free PMC article.
-
Trends in Cruciferous Vegetable Consumption and Associations with Breast Cancer Risk: A Case-Control Study.Curr Dev Nutr. 2017 Jul 18;1(8):e000448. doi: 10.3945/cdn.117.000448. eCollection 2017 Aug. Curr Dev Nutr. 2017. PMID: 29955715 Free PMC article.
-
3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial.Carcinogenesis. 2020 Oct 15;41(10):1395-1401. doi: 10.1093/carcin/bgaa050. Carcinogenesis. 2020. PMID: 32458980 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical